SCHEMBL4624293

SCHEMBL4624293

Oc1cccc2ccc(Oc3ccccc3)nc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 3/20 0.49
METAP2 P50579 2/20 0.49
PLAU P00749 1/20 0.49
NCF1 P14598 1/20 0.49
ALOX12 P18054 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAP4K4 O95819 1/20 0.45
SOS2 Q07890 1/20 0.45
PIM1 P11309 4/20 0.44
PIM2 Q9P1W9 3/20 0.43
TSHR P16473 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227590 0.87 METAP2 (0.57) KDM4EKMT2AMETAP2PLAUNCF1
SCHEMBL4626479 0.85 ALDH1A1 (0.47) KDM4EKMT2AMETAP2PLAUNCF1
SCHEMBL16511924 0.83 MAP4K4 (0.54) KDM4EKMT2AALDH1A1CYP1A2CYP2C9
SCHEMBL6993187 0.79 MAP4K4 (0.45) ALDH1A1MAP4K4PIM1PIM2TSHR
SCHEMBL15228636 0.79 BACE1 (0.49) KDM4EALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL15228726 0.79 DHODH (0.49) KDM4EKMT2AALOX12ALDH1A1MAP4K4
SCHEMBL4625590 0.78 MEN1 (0.56) KDM4EKMT2AMETAP2PLAUNCF1
SCHEMBL2118479 0.77 KDM4E (0.59) KDM4EKMT2AMETAP2PLAUNCF1
SCHEMBL4624601 0.77 KMT2A (0.48) KDM4EKMT2AMETAP2PLAUNCF1
SCHEMBL1043719 0.77 METAP2 (0.58) KDM4EKMT2AMETAP2PLAUNCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP claimed